MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Profile and progression of cognitive deficits in Progressive Supranuclear Palsy, Multiple System Atrophy and Parkinson’s Disease

E. Fiorenzato, A. Antonini, V. Camparini, L. Weis, C. Semenza, R. Biundo (Venice, Italy)

Meeting: 2019 International Congress

Abstract Number: 1679

Keywords: Cognitive dysfunction, Multiple system atrophy(MSA): Clinical features, Progressive supranuclear palsy(PSP)

Session Information

Date: Wednesday, September 25, 2019

Session Title: Cognition and Cognitive Disorders

Session Time: 1:15pm-2:45pm

Location: Agora 3 East, Level 3

Objective: This study investigated neuropsychological tests most sensitive in differentiating progressive supranuclear palsy (PSP) from Parkinson’s disease (PD) and multiple system atrophy (MSA), and in detecting cognitive changes at follow-up.

Background: Cognitive impairment is frequent in PSP, but its characteristics and progression need to be properly defined.

Method: We evaluated 35 PSP with Richardson’s syndrome (PSP-RS), 30 MSA as well as 65 age-, sex-, and education-matched PD with an extensive clinical and neuropsychological assessment, allowing Level II cognitive diagnosis. Eighteen PSP, 12 MSA and 30 PD had a second evaluation 12-18-month (mean 15 months) after the first assessment.

Results: In PSP, Montreal Cognitive Assessment (MoCA), verbal fluencies (phonemic and semantic tasks), Stroop test, Digit Span Sequencing (DSS), incomplete letters of Visual Object and Space Perception (VOSP) and Benton’s Judgment of Line Orientation (JLO) performance were significantly impaired at baseline compared to PD and MSA. Executive and visuo-spatial abilities declined longitudinally in PSP, but not in PD and MSA. After 1.5 year, 16% of PSP converted to dementia.

Conclusion: Our study provides evidence that cognitive decline is more severe and rapid in PSP than PD and MSA. MoCA, verbal fluency, DSS and Benton’s JLO are valuable tests to detect cognitive progression in PSP and may be proposed as biomarker for research protocols to assess efficacy of disease modification strategies.

To cite this abstract in AMA style:

E. Fiorenzato, A. Antonini, V. Camparini, L. Weis, C. Semenza, R. Biundo. Profile and progression of cognitive deficits in Progressive Supranuclear Palsy, Multiple System Atrophy and Parkinson’s Disease [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/profile-and-progression-of-cognitive-deficits-in-progressive-supranuclear-palsy-multiple-system-atrophy-and-parkinsons-disease/. Accessed May 13, 2025.
  • Tweet
  • Email
  • Print

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/profile-and-progression-of-cognitive-deficits-in-progressive-supranuclear-palsy-multiple-system-atrophy-and-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Patients with Essential Tremor Live Longer than their Relatives
  • #23624 (not found)
  • The hardest symptoms that bother patients with Parkinson's disease
  • Three cases of early tremor in the course of Guillain-Barré Syndrome
  • The impact of gastric acid suppressants and antacids on levodopa plasma concentration in patients with Parkinson’s disease
  • To be or not to bupropion: a drug-induced parkinsonism?
  • The Role of MRI and DaTscan in Vascular Parkinsonism: A Case Report
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley